Rajiv Radhakrishnan

Rajiv Radhakrishnan

Auto-generated profile, based on publicly available information

Rajiv Radhakrishnan

Department of Psychiatry, Yale University, New Haven, CT, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2014 in Frontiers in Psychiatry
Verified
Journal Article
Open access
PDF file
RRRajiv Radhakrishnan
Rajiv Radhakrishnan
SWSamuel T. Wilkinson
Samuel T. Wilkinson
DDDeepak Cyril D’Souza
Deepak Cyril D’Souza
Cannabis is the most commonly used illicit drug worldwide, with approximately 5 million daily users worldwide. Emerging evidence supports a number of associations between cannabis and psychosis/psychotic disorders, including schizophrenia. These associations based on case-studies, surveys, epidemiological studies, and experimental studies indicate that cannabinoids can produce acute, transient effects; acute, persistent effects as well as delayed, persistent effects that recapitulate the psychopathology and psychophysiology seen in psychotic illness such as schizophrenia. Acute exposure to both cannabis and synthetic cannabinoids (Spice/ K2) can produce a full range of transient psychotomimetic symptoms, cognitive deficits, and psychophysiological abnormalities that bear a striking resemblance to symptoms of schizophrenia. In individuals with an established psychotic disorder, cannabinoids can exacerbate symptoms, trigger relapse, and have negative consequences on the course of the illness. Several factors appear to moderate these associations, including family history, genetic factors, history of childhood abuse, and the age at onset of cannabis use. Exposure to cannabinoids in adolescence confers a higher risk for psychosis outcomes in later life and the risk is dose-related. Individuals with polymorphisms of COMT and AKT1 genes may be at increased risk for psychotic disorders in association with cannabinoids, as are individuals with a family history of psychotic disorders or a history of childhood trauma. The relationship between cannabis and schizophrenia fulfills many but not all of the standard criteria for causality, including temporality, biological gradient, biological plausibility, experimental evidence, consistency, and coherence. At the present time, the evidence indicates that cannabis may be a “component cause” in the emergence of psychosis, and warrants serious consideration from the point of view of public health policy.

1 January 2012 in Indian Journal of Psychiatry
Verified
Journal Article
Open access
PDF file
RRRajiv Radhakrishnan
Rajiv Radhakrishnan
CAChittaranjan Andrade
Chittaranjan Andrade
Suicide is the third leading cause of death among young adults worldwide. There is a growing recognition that prevention strategies need to be tailored to the region-specific demographics of a country and to be implemented in a culturally-sensitive manner. This review explores the historical, epidemiological and demographic factors of suicide in India and examines the strategies aimed at the prevention of suicide. There has been an increase in the rates of suicide in India over the years, although trends of both increases and decline in suicide rates have been present. Distinct from global demographic risk factors, In India, marital status is not necessarily protective and the female: male ratio in the rate of suicide is higher. The motives and modes of suicide are also distinct from western countries. Preventive strategies implemented at a community level and identifying vulnerable individuals maybe more effective than global strategies.

14 January 2016 in Annual Review of Medicine
Verified
Journal Article
Closed access
SWSamuel T. Wilkinson
Samuel T. Wilkinson
SYStephanie Yarnell
Stephanie Yarnell
RRRajiv Radhakrishnan
Rajiv Radhakrishnan
SBSamuel A. Ball
Samuel A. Ball
DDDeepak Cyril D'SOuza
Deepak Cyril D'SOuza
Marijuana is becoming legal in an increasing number of states for both medical and recreational use. Considerable controversy exists regarding the public health impact of these changes. The evidence for the legitimate medical use of marijuana or cannabinoids is limited to a few indications, notably HIV/AIDS cachexia, nausea/vomiting related to chemotherapy, neuropathic pain, and spasticity in multiple sclerosis. Although cannabinoids show therapeutic promise in other areas, robust clinical evidence is still lacking. The relationship between legalization and prevalence is still unknown. Although states where marijuana use is legal have higher rates of use than nonlegal states, these higher rates were generally found even prior to legalization. As states continue to proceed with legalization for both medical and recreational use, certain public health issues have become increasingly relevant, including the effects of acute marijuana intoxication on driving abilities, unintentional ingestion of marijuana pro...

1 January 2019 in The Lancet Psychiatry
Verified
Journal Article
Closed access
DDDeepak Cyril D'Souza
Deepak Cyril D'Souza
JCJose Cortes-Briones
Jose Cortes-Briones
GCGina Creatura
Gina Creatura
GBGrai Bluez
Grai Bluez
HTHalle Thurnauer
Halle Thurnauer
PSPatrick D Skosnik
Patrick D Skosnik

1 June 2016 in Biological Psychiatry
Verified
Journal Article
Closed access
MRMohini Ranganathan
Mohini Ranganathan
JCJose Cortes-Briones
Jose Cortes-Briones
RRRajiv Radhakrishnan
Rajiv Radhakrishnan
HTHalle Thurnauer
Halle Thurnauer
BPBeata Planeta
Beata Planeta
DDDeepak Cyril D’souza
Deepak Cyril D’souza

1 April 2016 in Biological Psychiatry
Verified
Journal Article
Closed access
MSMohamed Sherif
Mohamed Sherif
RRRajiv Radhakrishnan
Rajiv Radhakrishnan
DDDeepak Cyril D’sOuza
Deepak Cyril D’sOuza
MRMohini Ranganathan
Mohini Ranganathan